NBP
NovaBridge Biosciences
$1.90
+0.04 (+2.15%)
At close · Jul 10
Market Cap
$493.60M
Shares
265,377,891
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$632K
+140.7%
FY2023
Net Income
-$46.27M
-108.1%
FY2025
Operating Margin
-11395.09%
FY2023
Diluted EPS
-$0.21
-75%
FY2025
Operating Cash Flow
-$20.6M
+60.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| — | — | $632K | -$1.55M | $88.03M | $1.54B | $30M | $53.78M | $11.56M | — | |
| CNY | — | — | — | 27.24M | 46.43M | 0 | 0 | — | — | — |
| $62.91M | $21.77M | $21.45M | $22.55M | $1.21B | $984.69M | $840.42M | $426.03M | $267.08M | $43.6M | |
| $31.36M | $29.66M | $28.16M | $28.98M | $899.94M | $402.41M | $654.55M | $66.39M | $25.44M | — | |
| CNY | — | — | 778K | 778K | 778K | 1.56M | — | — | — | — |
| — | $300K | $500K | $200K | $13.8M | $12.7M | $9.8M | $6.7M | $1.6M | — | |
| $94.27M | $51.43M | $72.65M | $51.53M | — | — | — | — | — | — | |
| -$94.27M | -$51.43M | -$72.02M | -$53.08M | — | — | — | — | — | — | |
| — | — | -11395.09% | — | — | — | — | — | — | — | |
| — | -$51.13M | -$71.52M | -$52.88M | — | — | — | — | — | — | |
| CNY | — | — | 722K | 9000 | 0 | 957K | 2.99M | 11.7M | 5.64M | — |
| $7.61M | $7.49M | $9.29M | $4.95M | $21.33M | $24.23M | $30.57M | $4.6M | $858K | — | |
| -$1.68M | -$4.72M | -$8.09M | -$28.27M | $83.16M | $412.89M | -$20.21M | -$16.78M | $1.53M | — | |
| — | -$1.04M | -$11.4M | -$64.71M | -$367.88M | -$108.59M | $0 | — | — | — | |
| -$88.34M | -$49.7M | -$82.22M | -$141.1M | -$2.33B | $483.15M | -$1.45B | -$401.11M | -$298.24M | — | |
| $0 | $0 | $0 | $103K | -$3.15M | $12.23M | $0 | $1.72M | — | — | |
| -$46.27M | -$22.23M | -$207.73M | -$371.05M | -$2.33B | $470.92M | -$1.45B | -$402.83M | -$298.24M | — | |
| — | — | -32868.51% | — | -2648.7% | 30.53% | -4839.83% | -749.02% | -2580.82% | — | |
| -$42.07M | — | — | — | — | — | — | — | — | — | |
| CNY | — | — | -1.47B | -2.51B | -2.33B | 470.92M | -1.49B | -402.83M | -298.24M | — |
| -$38.11M | -$28.62M | -$202.12M | -$365.47M | -$2.47B | $350M | -$1.44B | -$349.14M | -$292.32M | — | |
| USD/shares | -$0.21 | -$0.12 | -$1.09 | -$1.96 | -$13.35 | $3.51 | -$201.19 | -$61.70 | -$51.93 | — |
| USD/shares | -$0.21 | -$0.12 | -$1.09 | -$1.96 | -$13.35 | $3.00 | -$201.19 | -$61.70 | -$51.93 | — |
| shares | 220.26M | 186.73M | 191.42M | 189.79M | 174.71M | 134.16M | 7.38M | 6.53M | 5.74M | — |
| shares | 220.26M | 186.73M | 191.42M | 189.79M | 174.71M | 157.23M | 7.38M | 6.53M | 5.74M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2023-12-31 |
|---|---|
| Oncology | $632,000 |
By Product & Service (USD)
| Component | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Licensing and Collaboration | $632,000 | — | — |
| Licensing and Collaboration | — | -$1,551,000 | $6,295,000 |
| Supply of Investigational Products | — | — | $7,518,000 |